Evidence map›Paper›PMID 37569713›Full record

ArticleInternational journal of molecular sciences2023

Pictilisib-Induced Resistance Is Mediated through FOXO1-Dependent Activation of Receptor Tyrosine Kinases in Mucinous Colorectal Adenocarcinoma Cells.

Murali R Kuracha, Venkatesh Govindarajan, Brian W Loggie, Martin Tobi, Benita L McVicker

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of molecular sciences, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.2field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. ACS pharmacology & translational science · 2024
    Article
  3. Novel Therapeutic Approaches for Colorectal Cancer Treatment.International journal of molecular sciences · 2024
    Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 1 country.

Murali R KurachaDepartment of Internal Medicine, University of Nebraska Medicine, Omaha, NE 68198, USA.
Venkatesh GovindarajanDepartment of Medical Education, Creighton University School of Medicine, Omaha, NE 68178, USA.
Brian W LoggieDepartment of Surgery, Creighton University School of Medicine, Omaha, NE 68124, USA.
Martin TobiResearch and Development Service, Detroit VAMC, Detroit, MI 48201, USA.
Benita L McVickerDepartment of Internal Medicine, University of Nebraska Medicine, Omaha, NE 68198, USA.ORCID 0000-0001-7876-149X
Creighton University · USNebraska Medical Center · USJohn D. Dingell VA Medical Center · US

Funding

Alcohol-sensitized macrophages enhance colorectal carcinoma metastasis in the liverI01BX004127 · VA · OMAHA VA MEDICAL CENTER · PI MCVICKER, BENITA L., TOBI, MARTIN · 2019 to 2022
–
BLRD VA I01 BX004127
6 · The paper itself

Abstract

The phosphatidylinositol (PI3K)/AKT/mTOR axis represents an important therapeutic target to treat human cancers. A well-described downstream target of the PI3K pathway is the forkhead box O (FOXO) transcription factor family. FOXOs have been implicated in many cellular responses, including drug-induced resistance in cancer cells. However, FOXO-dependent acute phase resistance mediated by pictilisib, a potent small molecule PI3K inhibitor (PI3Ki), has not been studied. Here, we report that pictilisib-induced adaptive resistance is regulated by the FOXO-dependent rebound activity of receptor tyrosine kinases (RTKs) in mucinous colorectal adenocarcinoma (MCA) cells. The resistance mediated by PI3K inhibition involves the nuclear localization of FOXO and the altered expression of RTKs, including

Indexed as

AdenocarcinomaColorectal NeoplasmsForkhead Box Protein O1Forkhead Transcription FactorsHumansIndazolesPhosphatidylinositol 3-KinasesPhosphoinositide-3 Kinase InhibitorsProto-Oncogene Proteins c-aktReceptor Protein-Tyrosine KinasesSulfonamidesTyrosine2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidineForkhead Box Protein O1Forkhead Transcription FactorsFOXO1 protein, humanIndazolesPhosphatidylinositol 3-KinasesPhosphoinositide-3 Kinase InhibitorsProto-Oncogene Proteins c-aktReceptor Protein-Tyrosine KinasesSulfonamidesTyrosineFOXOmucinous colorectal adenocarcinomaspictilisib

Identifiers

PMID37569713
PMCPMC10418489
OpenAlexW4385491271

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.